Indian vaccine maker working on a range of low-priced products
Serum's offerings threaten to undercut brands from the world's biggest pharma firms
Add BT as a preferred sourceMumbai
ASIA'S biggest vaccine maker is working on a string of new low-priced offerings that threaten to undercut brands from the world's biggest pharmaceutical companies.
Serum Institute of India Ltd, which makes vaccines injected in 65 per cent of the world's children, is targeting newer vaccines, including one for the human papillomavirus (HPV) that could be available in late 2018 and sell at a third of the price of Merck & Co's blockbuster Gardasil. Also in development are vaccines for types of severe diarrhoea and pneumonia.
TRENDING NOW
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
Two-thirds of Sentosa Cove resales in the red, with average loss topping S$1 million since 2023
